
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health Inc. is positioned favorably due to the significant rise in GLP-1 drug prescriptions, which surged 587% from 2019 to 2024, indicating a growing market for effective obesity and diabetes treatments. The company’s emphasis on developing durable disease-modifying therapies, demonstrated by promising results from the REMAIN-1 trial and advancements in their GLP-1 PGTx program, underscores its potential to outperform current treatment options. Additionally, the anticipated scalability of manufacturing capabilities will support increased production as clinical programs progress, potentially enhancing the company’s competitive standing in the metabolic therapeutics space.
Bears say
Fractyl Health's stock outlook appears negative due to concerns surrounding its high cash burn associated with expanding development and commercial programs, which may not be sustainable without sufficient capital or revenue from milestones. Additionally, research highlights that patients with type 2 diabetes (T2D) face a progressive decline in β-cell function, which complicates treatment efficacy and could hinder patient outcomes. Lastly, the observed lower efficacy of Fractyl's GLP-1 therapies compared to pharmacologic alternatives raises questions about the company's ability to effectively address the treatment needs of T2D patients, potentially impacting its competitive positioning in the market.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares